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Polydiacetylenic nanoﬁbers as new siRNA vehicles
for in vitro and in vivo delivery†
P. Neuberg, a I. Hamaidi,b S. Danilin,b M. Ripoll,a V. Lindner,c M. Nothisen,a
A. Wagner, d A. Kichler, a T. Massfelder *b and J.-S. Remy *a
Polydiacetylenic nanoﬁbers (PDA-Nfs) obtained by photo-
polymerization of surfactant 1 were optimized for intracellular
delivery of small interfering RNAs (siRNAs). PDA-Nfs/siRNA com-
plexes eﬃciently silenced the oncogene Lim-1 in the renal cancer
cells 786-O in vitro. Intraperitoneal injection of PDA-Nfs/siLim1
downregulated Lim-1 in subcutaneous tumor xenografts obtained
with 786-O cells in nude mice. Thus, PDA-Nfs represent an innova-
tive system for in vivo delivery of siRNAs.
Since the discovery of RNA interference in 1998 by Andrew
Z. Fire and Craig C. Mello, many attempts have been made to
translate this strategy towards new approaches in the treat-
ment of cancers in particular through specific silencing of
deregulated oncogenes, responsible for cancer growth.1,2
Nevertheless, despite enormous eﬀorts in the design of car-
riers for siRNA, therapeutic success has been hampered by the
low eﬃciency of siRNA delivery when used in vivo.
Here, we report on a new siRNA delivery system based on
polydiacetylenic nanofibers, which have so far never been used
for the intracellular delivery of biomolecules. Diacetylenic surfac-
tants, based on a long C25 hydrocarbon chain containing conju-
gated triple bonds, are able to self-assemble into a large variety
of supramolecular structures. The diacetylenic DA systems can
be polymerized upon UV irradiation forming so-called PDA
(PolyDiAcetylenic) systems initially discovered by G. Wegner in
the early 1970s.3–5 E. Doris’s group pioneered on the exploration
of the micellar forms of PDA, which are mostly monodisperse
systems, for drug delivery.6,7 Variations on the polar headgroups
allowed for fine-tuning and optimization of their delivery pro-
perties. Indeed, cationic PDA-micelles promoted gene delivery
while neutral oligo-ethylene decorated PDA-micelles favored
hydrophobic drug formulation.8,9 On the other hand, the intro-
duction of pH sensitive imidazole groups (such as compound 2
in Fig. 1), allowed for eﬃcient in vitro siRNA delivery.10
In initial formulation assays, we observed that diacetylenic
surfactants 1 and 2 spontaneously reorganized in opaque gel-
like structures upon prolonged storage at 5 °C under neutral
or basic pH. This observation is in accordance with a similar
gelation of PDA surfactants we described for propargyl-
ammonium PDA surfactants.11 The diacetylenic surfactants 1
and 2 become extremely photosensitive in this gel like solu-
tions, and they polymerize upon short irradiation times at
254 nm into deep blue aggregates. Photopolymerized PDA
structures consisting in 2D monolayers (ribbons, in the blue
form), twisted spirals or tubular structures are described in the
literature, often in association with chiral headgroups, such as
small peptides and modified amino acids.12–15
The polymeric aggregates formed by photopolymerization
of 1 or 2 dissolve under acidic conditions to form small red
nanofibers, which are highly fluorescent. The red transparent
solutions of polymerized histidine surfactant 2 are composed
of extended fibers, ranging from 10 to 50 µm in length. They
are highly resistant to shearing forces. They could not be
Fig. 1 (A) Structure of diacetylenic surfactant 1 and histidine analogue
2. (B) Low voltage electron microscopy of PDA-Nfs obtained from 1
after photopolymerization and sonication (red ﬂuorescent form).
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further fragmented even under harsh conditions (such as soni-
cation or heating) to obtain smaller sized fibers, such as would
be required for cell delivery assays. Optimization of the formu-
lations with a diverse set of diacetylenic surfactants allowed us
to select surfactant 1 as the best candidate for intracellular
delivery as it could form consistently smaller fibers, termed
here PDA-Nfs (micrographs of the fibers obtained from 1 and 2
are shown in ESI-1A and B†). The PDA-Nfs formed with surfac-
tant 1 were then explored in in vitro and in vivo siRNA transfec-
tion experiments.
The selected diacetylenic monomer (1) has been synthe-
tized by coupling 4,7,10-trioxa-1,13-tridecanediamine on the
NHS ester of commercial 10,12-pentacosadiynoic acid (see ESI
for detailed synthesis procedure, and Fig. S2 and S3† for the
NMR and mass spectra of compound 1).
The optimized formulations were obtained by injecting hot
concentrated solutions of 1 into 30% ethanol/water at 5 °C.
The obtained gel-like solutions were polymerized under hard
UV-light at 254 nm in a UV-Crosslinker, where they converted
into red PDA-Nfs (see ESI for detailed procedure and Fig. S4
and S5†). Such color change are supposed to originate from
distortion of π-conjugated backbone of PDA, due to a tran-
sition from 2D monolayer, sheet like structures into tubular
twisted forms.16 Some PDA-liposome biosensors rely on these
chromatic properties, where a physical or chemical stimulus
induces this blue-red color change.17,18 Some are used for
diagnosis of prostate cancer.19
We further characterized these PDA-Nfs of 1 by physico-
chemical methods, such as UV-Vis and fluorescence spec-
troscopy, dynamic light scattering and low voltage electron
microscopy (see ESI† for detailed biophysical characterization,
Fig. 1B, 2A, S4 and S5†).
The fluorescence absorption and excitation spectra are
shown in Fig. 2A. Interestingly the maximum excitation wave-
length is separated by a wide bandwidth between 550 and
646 nm (Stokes shift of about 100 nm).
The hydrodynamic diameter of the PDA-nanofibers was
measured by dynamic light scattering experiments. Their
mean size by intensity is 780 nm. The same fiber solution
diluted 10-fold showed a zeta potential of +52 mV, confirming
the presence of positively charged amine functions at the
outer side of the nanofibers (see Fig. S6†).
Complexation of anionic siRNA molecules in neutral buﬀer
conditions, and analysis by gel electrophoresis show that
siRNA is complexed at low N/P values around 4. This N/P ratio
is defined as the total amine content of the PDA-Nfs versus the
number of phosphate groups present in the siRNA (see
Fig. S7A†). Interestingly, similar complexation has been
achieved with extensively dialyzed nanofibers, where all
residual monomer has been removed, confirming indirectly
the high polymerization eﬃciency under the conditions of
nanofiber preparation (see ESI for dialysis purification and
complexation assays, in Fig. S7B†).
Up to 80% silencing could be obtained with 10 nM siLuc
(siRNA targeting the luciferase reporter gene; at N/P values
from 12 to 20; see Fig. 3). Total protein quantification of trans-
fected cells, compared to untreated ones, shows low toxicity of
the PDA-Nfs formulated siRNAs.
The PDA-Nfs/siRNA complexes also maintained high silen-
cing eﬃciency in 10% serum conditions (see Fig. S8†), and
they compared favorably to commercial transfection reagent
INTERFERin (from POLYPLUS-transfection).
In order to prove the eﬃciency of the PDA-Nfs/siRNA com-
plexes on another cell line, the 786-O human renal cancer cells
was selected. 786-O cell line represents one of the most used
model to study Clear Cell renal Cell carcinoma (CCC). CCC is
the most common and aggressive form of kidney cancer in
adult (>75% of kidney cancer cases), and remains resistant to
current anticancer therapies.
Luciferase expressing 786-O-Luc cell line was used for the
optimization of the delivery conditions of siRNA with the
PDA-Nfs/siRNA. As with the A549-Luc cells, a highly eﬃcient
silencing of the luciferase reporter gene was observed in
786-O-Luc cells, as indicated by direct bioluminescence
Fig. 2 (A) Fluorescence excitation (green) and emission (orange)
spectra of PDA-Nfs (1). (B) Fluorescence microscopy of A549-Luc cells
transfected with PDA-Nfs/siRNA showing an overlay of phase contrast
picture and ﬂuorescence image. A strong internalization of PDA-Nfs/
siRNA complexes (with a N/P = 13 and a ﬁnal siRNA concentration of 10
nM) is observed after 24 hours by ﬂuorescence microscopy using the
intrinsic ﬂuorescence of the PDA-Nfs.
Fig. 3 siLuc delivery in A549-Luc cell line at 10 nM siRNA concentration
and various N/P ratios (optimal N/P for this cell line at N/P 13.5 shows a
silencing of 82%). Viability is measured by total protein quantiﬁcation
and compared to untreated cells.
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imaging of the cell culture plates. In this cell line the optimal
N/P values ranged between N/P 5 and 10 (see ESI for bio-
luminescence assay and cell density measurements, Fig. S9†).
Dr. Massfelder’s group has recently identified the develop-
mental transcription factor Lim-1 as an oncogene in CCC regu-
lating tumor growth.20,21 The selected 786-O cell line expresses
constitutively the Lim-1 oncogene.20
We evaluated the capacity of PDA-Nfs to silence endogenous
Lim-1 in 786-O. As shown in Fig. 4, the PDA-Nf/siLim allowed
to inhibit the expression of Lim-1 by more than 80% at the
various PDA-Nfs concentrations tested. The relative expression
of Lim-1 has been measured by qPCR analysis in comparison
to cyclophilin used as a reference gene (48 hours of treatment
at 10 nM siLim1 concentration; Fig. 4). The RNA interference
eﬃciency has been calculated by comparing the level of Lim-1
expression on PDA-Nfs/siLim1 treated cells to that of PDA-Nfs/
siCtl. As a positive control for siRNA transfection we used
jetPrime reagent (from POLYPLUS-transfection).
In order to evaluate the capacity of the PDA-Nfs to silence a
gene that is even highly expressed, we used a stable 786-O
clone overexpressing Lim-1 by up to 80 times. This clone was
treated with 10 nM of siLim1 and siCtl complexed with 4 µM
amine concentration of PDA-Nfs (N/P = 10). RT-qPCR analysis
shows a decrease of Lim-1 expression by approx. 90% (see
Fig. S10†).
Finally, we tested the eﬃcacy of nanofibers to carry small
interfering RNA in vivo. Nude mice bearing subcutaneous
human 786-O tumors were treated by a single intraperitoneal
injection of PDA-Nf/siLim (n = 6), PDA-Nfs/siCtl (n = 5) com-
plexes or untreated (n = 4). Forty eight hours after treatment,
animals were euthanized and the tumors were harvested. Each
tumor was cut in 2 parts, one for Western blot analysis, and
the other part for RT-qPCR analysis. RT-qPCR analysis showed
a significant decrease of Lim-1 expression in PDA-Nfs/
siLim1 group, as compared to PDA-Nfs/siCtl (see Fig. 5A; and
ESI† for statistical analysis). These results were confirmed by
Western blot analysis on the pooled samples. We clearly
observed a decrease of Lim-1 expression in PDA-Nfs/siLim
group as compared to PDA-Nfs/siCtl or untreated groups
(Fig. 5B, experimental details in ESI†).
The siRNA/PDA-Nfs complexes used in these in vivo experi-
ments were also characterized by DLS and zeta potential measure-
ment. At the chosen N/P = 6 ratio the PDA-Nfs concentration is
suﬃcient to maintain positive zeta potential values >35 mV of the
siRNA complexes, ensuring that the complexes do not tend to
aggregate (see ESI for detailed analysis, and Fig. S11†).
Biodistribution of i.p. injected PDA-Nf/siRNAs was assessed
by histological analysis of sections from paraﬃn embedded
organs of mice euthanized at 1 hour or at 48 hours after
administration of PDA-Nfs. At 1 h they were detected in blood
samples, as well as in various organs, such as the spleen (high
abundance), liver, lung and kidney by fluorescence microscopy
(see ESI for detailed experimental procedure and Fig. S12†).
However the fluorescence of the PDA-Nfs could not be detected
any more, neither in the organs from mice taken at 48 h, nor
in their blood samples. At this time point the PDA-Nfs seemed
metabolized or cleared from the body. This observation is in
accordance with a supposed progressive clearance by the
kidneys, as urine samples taken from mice taken at 48 h but
not at 1 h showed weak presence of PDA-Nfs. Furthermore the
fluorescent PDA-Nfs could also be detected in tumor samples
from mice sacrificed at 48 hours after i.p. administration,
where we have shown that they lead to specific silencing of the
Lim-1 oncogene (see ESI for detailed microscopic analysis of
the histological sections, and Fig. S13†). In all these experi-
ments mice had normal behavior and no signs of inflam-
mation nor discomfort were observed after injections. This
clearly shows that these new siRNA formulations are safe. We
note that some larger particles such as cationic tyrosine modi-
fied PEI-siRNA complexes are able to diﬀuse to tumor xenografts
after intraperitoneal injection.22 On the other hand elongated
multiwalled carbon nanotubes of µm length have been
described to be able to diﬀuse in the living organism reaching
various organs dependent on the shape and nature of the nano-
tubes.23 All animal procedures were performed in accordance
with the Guidelines for Care and Use of Laboratory Animals of
Fig. 4 Reduced expression level of endogenous Lim-1 gene in 786-O
cells after 48 h treatment with speciﬁc (siLim1) and control siRNA at 10
nM siRNA concentration and various concentrations of PDA-Nfs (N/P =
5 to N/P = 8). JetPRIME reagent (POLYPLUS-transfection) was used as a
positive control for siRNA delivery.
Fig. 5 In vivo silencing eﬃciency of siRNA targeting Lim-1 oncogene
(siLim1) in subcutaneous xenografted 786-O cells in nude mice. (A)
qPCR quantiﬁcation of the expression level of Lim-1 gene relative to the
housekeeping gene 18S. Average results shown as mean ± s.e.m.,
Untreated n = 4, PDA-Nfs/siCtl n = 5, PDA-Nfs/siLim1 n = 6; **P < 0.01
from Ctl; *P < 0.05 from siCtl (B) Western blot analysis of the expression
level of the Lim-1 gene as compared to the actin protein. Each plot rep-
resents a pool of all tumor extracts from the same group.
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Animal Care Facility at the Faculty of Medicine at the University
of Strasbourg (France) and were approved by the Animal Ethics
Committee of CREMAS (Comité régional d’éthique en matière
d’expérimentation animale de Strasbourg).
Conclusion
In the present work, we were able to show for the first time
that PDA-Nfs can be promising delivery agents for siRNAs.
Surfactant (1) allows for the generation of relatively small
nanofibers that are able to internalize eﬃciently into cells. The
PDA nanofibers associated with a siRNA targeting a reporter
gene (luciferase gene in A549-Luc and 786-O-Luc cell lines)
lead to a very eﬃcient silencing.
In vitro, the PDA-Nfs/siLim1 eﬃciently silenced by more
than 80% the expression of the Lim-1 oncogene in the 786-O
human CCC cell line. Furthermore, when administered intra-
peritoneally, the PDA-Nfs were able to deliver siRNA into sub-
cutaneously grown tumors, where they led to specific silencing
of the targeted Lim-1 oncogene. By analyzing the biodistribu-
tion of the PDA-Nfs, we proved that these nanofiber systems
diﬀuse in the bloodstream and reach various organs as well as
the targeted tumors. They were cleared from the body 48 hours
post-injection presumably by renal excretion, as the PDS-Nfs
could then be detected in urine samples.
Taken together, we found that PDA-Nfs are a promising and
highly eﬃcient new class of self-organized siRNA vectors for
in vitro and in vivo applications, with good biodistribution pro-
files in the body.
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